Dr Susan Voglmaier – Driving Forward Training and Research in Psychiatry

Oct 23, 2019 | Biology, Health and Medicine

In recent years, dramatic advances have been made in brain science and molecular genetics. However, there is currently a shortage of psychiatrists with the scientific training necessary to take this knowledge and apply it in the clinic. Psychiatrist and neuroscience researcher, Dr Susan Voglmaier of the University of California, San Francisco, runs a research training program that supports the next generation of research scientists in the field of psychiatry. Dr Voglmaier believes that by training doctors in scientific techniques and methods, we may come to better understand mental illness and provide more effective treatments for psychiatric diseases in the future.

Training the Next Generation of Psychiatrists

The Psychiatry Research Resident Training Program at the University of California, San Francisco (UCSF) is a specialised program that aims to increase the number of qualified research psychiatrists. The program also focuses on fostering the integration of biology and psychology in advancing the treatment of neuropsychiatric disease. Dr Susan Voglmaier directs the program, where she oversees the research and clinical training of psychiatrists. Participants of the program are MDs, many of whom already have PhDs, who undertake a comprehensive training program that provides them with neuroscience or clinical research training and career mentorship in classroom, laboratory, and clinical settings. Partially funded by the National Institute of Mental Health, the program includes neuroscience workshops, leadership experiences, and individualised training to allow psychiatrist-scientists to establish and maintain the running of scientific research projects alongside their clinical training.

Neurotransmitters: Deciphering Their Role in Mental Illness

In addition to leading the Research Resident Training program, Dr Voglmaier runs an active research lab that focuses on the study of specialised proteins that are found inside of nerve cells (neurons) in the brain, called vesicular neurotransmitter transporters. Neurotransmitters are chemical signals that are transmitted rapidly (on the order of milliseconds) from one neuron to another, coordinating learning, memory, and action. Glutamate, an amino acid, is the most abundant neurotransmitter in the human brain and mediates neuronal excitation. Inside the cell, vesicular glutamate transporters (VGLUTs) package glutamate into specialised sacs or compartments called synaptic vesicles. When neurons receive electrical signals from other neurons, synaptic vesicles fuse with the cell membrane and release glutamate from the cell. When glutamate is detected by the receptors on a neighbouring neuron, this results in signal transmission. After neurotransmitter release, synaptic vesicles are broken down, reformed, and refilled with neurotransmitter for a new round of release.

There are three types of vesicular glutamate transporter, known as VGLUT 1, 2 and 3, with VGLUT1 and VGLUT2 being the most abundant. These two glutamate transporters are expressed in different areas of the brain as well as at different levels and times during the life of an organism. During development, VGLUT2 levels are highest in the womb, while VGLUT1 levels increase during brain maturation and are higher in adults compared to younger individuals. In general, VGLUT2 is expressed in glutamatergic pathways that transmit sensory information from the outside world, while VGLUT1 pathways transmit information from memory about meaning.

A precise balance of VGLUT1 and VGLUT2 containing synaptic terminals is needed to integrate information and coordinate output behaviour. For example, when a person sees a round, red object this information is transmitted via VGLUT2 pathways and is compared to information in the brain carried by VGLUT1 pathways, to identify whether the object is a ball or an apple, and whether s/he should throw it or eat it (Figure 1).

The formation of new synaptic vesicles and their loading with glutamate need to keep up with the rapid signaling demands of the cell. If this doesn’t happen, insufficient glutamate will be available for signal propagation. In the central nervous system, imbalance of glutamate signaling at the synapse is suspected to be involved in schizophrenia, major depressive disorder, and bipolar disorder. VGLUT1 and VGLUT2 each have sophisticated signals in their structure that control the take-up, transport, and release of glutamate from the synaptic vesicle as well as their sorting to reforming synaptic vesicles after they have fused with the cell membrane.

At UCSF, Dr Voglmaier’s research team have unravelled a number of the molecular mechanisms that allow glutamatergic synaptic vesicle proteins to recycle from the cell membrane at the synapse and allow glutamate to refill vesicles.

In recent studies, her team found that although the basic process of glutamate transport across the synaptic vesicle membrane by both forms of glutamate transporters is identical, the recycling of the synaptic vesicle from the cell membrane at the synapse of the neuron proceeds in very distinct ways depending on whether VGLUT1 or VGLUT2 is involved. The researchers showed that the speed of take-up and recycling of the transporters differs between VGLUT1 and VGLUT2 even in the same cell type, demonstrating that the proteins themselves control the rate of their recycling. This is an important and new finding, as previous studies had assumed that all synaptic vesicle proteins recycled equivalently. However, the scientists found that VGLUT1 exhibits faster rates of recycling than VGLUT2.

These differences in the speed of vesicle recycling likely shape the rate, amount, and pattern of how much glutamate is released at the synapse and that will subsequently be available for cell signaling. Synapses that contain VGLUT1 exhibit a lower initial probability of release of glutamate while synapses with higher levels of VGLUT2 exhibit a higher probability of release. By exploiting the acidic environment inside the synaptic vesicle and using fluorescent genetically-encoded tools to track VGLUTs under the microscope, Dr Voglmaier’s team were able to determine the makeup and function of the sorting signals and discovered additional proteins that interact with the two types of VGLUTs and mediate the differences between them.

Figure 1. The VGLUT1 and VGLUT2 pathways. Credit Susan Voglmaier.

VGLUTS and the Synaptic Vesicle Cycle

Structurally, VGLUT1 and VGLUT2 are identical with the exception of a few molecular differences at the head and tail ends of the proteins. The tail end of VGLUT1 is slightly different from that of VGLUT2, containing protein interaction domains not present in VGLUT2, and that appear to contribute to the faster recycling of VGLUT1. However, little is known about the mechanisms underlying VGLUT2 recycling. This motivated Dr Voglmaier and her team to examine how VGLUT2 recycles across synaptic membranes using the protein pHluorin.

The protein pHluorin, a pH-sensitive form of green fluorescent protein, is used in neuroscience to study neurotransmitter release. Dr Voglmaier and her team designed specialised forms of pHluorin for their studies. These consist of pHluorin fused to the side of the VGLUT facing the inside of the synaptic vesicle. The pH inside transmitter vesicles is acidic, and the VGLUT-pHluorin is non-fluorescent under these conditions. When vesicles are released, VGLUT-pHluorin is exposed to the extracellular space, which has a neutral pH, and the presynaptic terminal becomes brightly fluorescent. Following the re-internalization and reformation of the synaptic vesicles, the vesicles become re-acidified and the cycle can start again (Figure 2). The fusion of a green fluorescent molecule to VGLUT1 and VGLUT2 allowed the researchers to track their activities during neuronal signal transmission and determine how they influence the interactions of synaptic vesicle proteins, the reformation of synaptic vesicles, and the release of glutamate.

Findings from these studies confirmed that VGLUT2 recycles differently than VGLUT1. These results indicated that it is protein identity, not synaptic vesicle membrane or neuronal cell type, that controls sorting the rate and method of VGLUT uptake and release, and that VGLUT2 relies on distinct recycling mechanisms from VGLUT1. In addition, the team was able to identify interactions with other proteins that were crucial for VGLUT1 trafficking at the synaptic membrane.

Figure 2. VGLUT-pHluorin exposed to the extracellular space. Credit Susan Volgmaier.

Synthesised Medicine

When the biochemical mechanisms of a particular disease are elucidated, specialised drugs can be designed to target the condition at a microscopic level. These synthesised drugs can be made in the lab via a series of chemical reactions using molecular building blocks to create larger molecules with the desired makeup and confirmation. Examples include molecules with the potential to block a particular molecular mechanism from occurring by binding to a target, at the site of the reaction or elsewhere. These drugs can be tailored to be delivered at specific potencies to the tissue where they are needed, leaving surrounding cells unaffected.

The rate of modern drug synthesis and development methods continue to gain momentum, along with novel delivery and targeting systems, such as nanotechnology. The first step in drug creation and development is the study and understanding of the process of disease. Dr Voglmaier hopes that her work will lead to a sufficient understanding of the molecular pathways that could be exploited to invent new drugs to increase or decrease the recycling of glutamate and other important neurotransmitters at the synapse level.

The Future of Medicine and Mental Health

The research in Dr Voglmaier’s lab continues to provide excellent training for scientists in the field of neurobiology. In addition, through the UCSF Department of Psychiatry’s Research Resident Training Program she provides training and support to a new generation of psychiatric clinician-scientists, who work at all levels of analysis, from molecular and cellular biology, to human participant research, to health systems. Dr Voglmaier thus contributes to the development of mental health specialists with the ability to understand and integrate their psychiatric clinical practice with laboratory, clinical, and health services research. We can hope that other institutions will follow the UCSF blueprint created by Dr Voglmaier. As scientists work towards a better understanding of the brain biochemistry and molecular mechanisms of neuropsychiatric disease, it is hoped that the ability to synthesise specialised medicines for major mental illnesses, which have so far evaded effective treatment, will become the norm.

Reference
https://doi.org/10.33548/SCIENTIA426

Meet the researcher


Professor Susan Voglmaier

University of California, San Francisco
Weill Institute for Neurosciences
Kavli Institute for Fundamental Neuroscience
Department of Psychiatry
San Francisco, CA
USA

Professor Susan Voglmaier completed her MD and PhD in Neuroscience at the John Hopkins School of Medicine in 1997. She then completed her medical residency in psychiatry at the University of California, San Francisco (UCSF), where she also worked as a clinical and research fellow in both Psychiatry and Neurology. Dr Voglmaier is currently an attending psychiatrist in the Adult Psychiatric Clinics at UCSF where she specialises in psychotic, anxiety, and mood disorders and performs resident supervision and medical student teaching. In addition, she is an Associate Professor in the Department of Psychiatry at UCSF, where she studies the regulation of synaptic vesicle recycling and neurotransmitter release, methods to image these processes, and animal and cellular disease models. She has also been a Faculty Member in the Neuroscience Program at UCSF since 2007 and is the Co-Director of the Psychiatry Research Resident Training Program.

CONTACT

E: susan.voglmaier@ucsf.edu

W: http://voglmaierlab.com

http://voglmaierlab.ucsf.edu

http://neurograd.ucsf.edu/people/susan-voglmaier-md-phd

http://psych.ucsf.edu/rtp/research

T: @UCSFRRTP

FUNDING

National Institutes of Mental Health

BBRF/NARSAD

Brain Research Foundation

International Mental Health Research Organization (IMHRO)

March of Dimes

UCSF Program for Breakthrough Biomedical Research

Whitehall Foundation

FURTHER READING

H Li, MS Santos, CK Park, et al, VGLUT2 trafficking is differentially regulated by adaptor proteins AP-1 and AP-3, Frontiers in Cellular Neuroscience, 2017, 11, 324.

AD Besterman, JK Williams, VI Reus, et al, The role of regional conferences in research resident career development: The California Psychiatry Research Resident Retreat, Academic Psychiatry, 2017, 41, 272–277.

MS Santos, H Li, SM Foss, SM Voglmaier, Protein interactions of the vesicular glutamate transporter VGLUT1, PLoS One, 2014, 9, e109824.

SM Foss, H Li, MS Santos, et al, Multiple dileucine-like motifs direct VGLUT1 trafficking, Journal of Neuroscience, 2013, 33, 10647–60.

MS Santos, CK Park, SM Foss, et al, Sorting of the vesicular GABA transporter to functional vesicle pools by an atypical dileucine-like motif, Journal of Neuroscience, 2013, 33, 10634–46.

H Li, SM Foss, YL Dobryy, et al, Concurrent imaging of synaptic vesicle recycling and calcium dynamics, Frontiers in Molecular Neuroscience, 2011, 4, 34.

Z Hua, S Leal-Ortiz, SM Foss, et al, v-SNARE composition distinguishes synaptic vesicle pools, Neuron, 2011, 71, 474–87.

 

Creative Commons Licence
(CC BY 4.0)

This work is licensed under a Creative Commons Attribution 4.0 International License. Creative Commons License

What does this mean?

Share: You can copy and redistribute the material in any medium or format

Adapt: You can change, and build upon the material for any purpose, even commercially.

Credit: You must give appropriate credit, provide a link to the license, and indicate if changes were made.

Subscribe now!


More articles you may like

Dr Mark Herzberg – Calprotectin – From Natural Antimicrobial to Anti-tumour Therapeutic?

Calgranulins are relatively small proteins, usually around 100 amino acids long. Calprotectin is a complex of two of these small proteins, S100A8 and S100A9, getting its name from its protective, antimicrobial properties. Dr Mark Herzberg at the University of Minnesota, USA, has extensively researched the antimicrobial action of this protein complex, and this knowledge is now leading serendipitously to the development of potential therapeutic agents for certain types of human cancer.

Dr Rakesh S. Chandran – Sustainable Weed Coexistence in Corn Crops

Agricultural weeds have the potential to cause significant crop loss. As such, conventional weed management practices have aimed to keep crop fields free from weeds through the broad application of herbicides. However, these practices have damaging consequences on the surrounding environment. Dr Rakesh Chandran and his team in the Agriculture and Natural Resources Department of West Virginia University have developed a more sustainable herbicide application regime that allows weeds to coexist with corn crops at acceptable levels, with the aim of improving environmental health without significantly sacrificing crop yield.

Dr Shikha Nangia – The Blood-Brain Barrier: More than Just a Barrier

Neurodegenerative disorders present a major cause of death and disability worldwide. Treatments are typically expensive, non-efficient, and invasive. Although scientists are committed to finding better treatment strategies, the challenge of penetrating the blood-brain barrier remains. This highly selective envelope protects our brain from harmful substances but also prevents drugs from reaching the brain when needed. Dr Shikha Nangia at Syracuse University, USA, focuses on understanding the molecular structure of this complex interface to ultimately facilitate the transport of drugs across the blood-brain barrier.

Dr Shannon Westlake | Dr Kevin Hunt – Human Elements of Pollinator Conservation

The alarming decline of pollinating insects in recent years has garnered a wave of interest from the media, scientists and the public. This has resulted in a wealth of research into pollinator conservation, but despite this, adoption of beneficial practices that support pollinators has been low amongst private landholders. Dr Shannon Westlake and Dr Kevin Hunt of Mississippi State University have been investigating the human elements behind pollinator conservation, with the aim of developing targeted outreach and support programs to improve the uptake of conservation efforts amongst landholders.